Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics (BOLT)
NASDAQ:BOLT
Holding BOLT?
Track your performance easily
BOLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $1.56
Previous CloseN/A
Volume72.19K
Average Volume (3M)191.84K
Market Cap
$19.52M
Enterprise Value-$11.63M
Total Cash (Recent Filing)$13.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Mar 26, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding38,273,003
10 Day Avg. Volume157,509
30 Day Avg. Volume191,837
Standard Deviation0.20
R-Squared0.05
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.00
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.60
Enterprise Value/Revenue-1.19
Enterprise Value/Gross Profit-1.48
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$1.75Price Target Upside257.14% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bolt Biotherapeutics News
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Changes and Appointments
PremiumCompany Announcements
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look
PremiumCompany Announcements
Bolt Biotherapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBDC-3042 has progressed to its final Ph 1 monotherapy dose level with no observed dose-limiting toxicities and signs of dose-dependent pharmacodynamics.
Financial StabilityThe company had $84.4M in cash and equivalents, and management expects it has a cash runway through mid-2026.
Preclinical EfficacyPreclinical work with BDC-4182 demonstrated efficacy across several preclinical models, and was well tolerated in non-human primates.
Bears Say
Analyst RatingAnalyst maintains a Neutral rating and has no price target as more clarity on the company’s pipeline is awaited.
Clinical TrialsThe stock is expected to remain pressured until clinical trials play out in 2025.
Financial PerformanceBolt reported 3Q24 revenue of $1.1M and EPS of ($0.40), compared to estimates of $1.7M and ($0.38), respectively.
---
Ownership Overview
11.18%
Insiders
3.95% Mutual Funds
0.05% Other Institutional Investors
81.59% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $0.47 and its highest was $1.56 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $19.52M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Mar 26, 2025 which is in 52 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.06.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics does not currently pay dividends.
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -0.37.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 38,273,003 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
---
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
---
Technical Analysis
Fate Therapeutics
―
Iovance Biotherapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
Immatics
―
---